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CFR01_AE cladeSeveral studies have shown that the early virus population present in HIV-1 infected infants usually is homo-
geneous when compared to the highly diversiﬁed viral population present at delivery in their mothers. We
explored the antigenic and functional properties of pseudotyped viruses expressing gp120 encoded by env
clones issued from four mother–infant pairs infected by CRF01_AE viruses. We compared their sensitivity
to neutralization and to entry inhibitors, their infectivity levels and the Env processing and incorporation
levels. We found that both transmitted viruses present in infants and the variants present in their chronically
infected mothers display a wide spectrum of biological properties that could not distinguish between them.
In contrast, we found that all the transmitted viruses in the infants were more sensitive to neutralization by
PG9 and PG16 than the maternal variants, an observation that may have implications for the development of
prophylactic strategies to prevent mother-to-child transmission.
© 2012 Elsevier Inc. All rights reserved.Introduction
Mother-to-child transmission (MTCT) is the leading source of
human immunodeﬁciency virus (HIV) infection in children. In the
absence of anti-retroviral prophylaxis, transmission can occur during
pregnancy (in utero), during labor and delivery (intrapartum), or
postnatally through breastfeeding (Scarlatti, 2004). Although infants
have been found occasionally to be infected by a heterogeneous popu-
lation of multiple maternal viral variants, molecular studies of MTCT
have shown that, despite a heterogeneous viral population in the
mother, homogeneous viral variants are generally transmitted to the
infant, suggesting the selection of a limited number of maternal viral
variants for establishment of a new infection in the infant (Ahmad
et al., 1995; Dickover et al., 2001; Kishko et al., 2011; Lamers et al.,
1994; Pasquier et al., 1998; Russell et al., 2011; Samleerat et al., 2008;
Scarlatti et al., 1993b; Verhofstede et al., 2003; Wolinsky et al., 1992;
Zhang et al., 2010b).cine, 10 blvd Tonnellé, 37032
Thenin),
-tours.fr (M. Braibant).
rights reserved.Maternal neutralizing antibodies (Nabs) are among the selective
factors that are potentially responsible for this genetic bottleneck.
Maternal antibodies of the IgG class cross the placenta into the fetal
bloodstream, reaching high levels in the fetus at the end of pregnancy
and protecting the infant against infection by numerous pathogens
(Englund et al., 1998; Safrit et al., 2004). Therefore, MTCT of HIV-1
provides a model for studying the role of passively acquired antibodies
present in the infant prior to virus exposure. However, reported studies
have yielded conﬂicting results. Some studies have suggested a role of
maternal Nabs in reducing MTCT, showing that non-transmitting
mothers had more frequently detected or higher Nab responses than
mothers who transmitted the virus to their infant (Barin et al., 2006;
Bongertz et al., 2002; Lathey et al., 1999; Samleerat et al., 2009;
Scarlatti et al., 1993a), or that viruses transmitted to infants are escape
variants resistant to autologous maternal serum (Dickover et al., 2006;
Wu et al., 2006; Zhang et al., 2010a). In contrast, others did not observe
any difference neither in breadth or potency of neutralizing antibodies
between sera from transmitting and non-transmitting mothers
(Guevara et al., 2002; Hengel et al., 1998; Husson et al., 1995; Russell
et al., 2011), nor in the sensitivity to neutralization between trans-
mitted infant variants and maternal variants (Kishko et al., 2011;
Russell et al., 2011). In addition, a recent study exploring the role of
passively acquired HIV antibodies in exposed infants during
13S. Thenin et al. / Virology 426 (2012) 12–21breastfeeding suggested that the breadth and potency of the heterolo-
gous antibody response does not predict protection (Lynch et al.,
2011).
Very few studies have been done focusing on the viral characteris-
tics associated with MTCT, others than neutralization sensitivity. A
correlation between HIV-1 transmission to infants and replicative
ﬁtness of transmitted viruses was suggested (Kong et al., 2008) but
not conﬁrmed (Kishko et al., 2011). Independently, several studies
performed mainly on HIV-1 strains of subtypes A and C suggested
that variants with shorter variable loops lengths and fewer potential
N-linked glycosylation sites (PNGS) encoded by their env gene were
selected during MTCT (Russell et al., 2011; Wu et al., 2006; Zhang et
al., 2010b). In contrast, we and others did not observe these charac-
teristics among env genes from mother–infant pairs infected with
variants of B and CRF01_AE clades (Kishko et al., 2011; Samleerat et
al., 2008). These discordant results may suggest that, similarly to
what was observed during horizontal transmission, molecular prop-
erties linked to transmissibility could be subtype-speciﬁc (Chohan
et al., 2005; Derdeyn et al., 2004; Frost et al., 2005). Nevertheless, in
our study performed on CRF01-AE env variants of mother–infant
pairs, we found that two PNGS, N301 in V3 and N384 in C3, were con-
served in almost all infants' variants but were not uniformly present
in variants from mothers. We hypothesized that these two PNGS
may confer a selective advantage for transmission of the virus to the
infants (Samleerat et al., 2008).
In the present study, we compared the biological properties of the
virus conferred by the envelope of maternal and infant viral variants
issued from four mother–infant pairs infected by HIV-1 of the CRF01_AE
clade, in order to explore their associationwith the restrictive transmis-
sion of the virus. A better understanding of antigenic and functional
properties of transmitted viral variants may help to the development
of vaccines or improved prophylactic strategies to prevent MTCT.
Results
HIV-1 mother–infant pairs (MIPs)
We selected HIV-1 CRF01_AE env sequences (V1 to V5 region of
gp120) from four previously described MIPs [0377, 0858, 0978 and
1021; (Samleerat et al., 2008)]. Maternal env sequences were
obtained from peripheral blood samples collected at delivery and
infant env sequences from plasma samples obtained at the ﬁrst time
point at which the HIV-1 DNA PCR results was positive. One infant
(0858) was positive at birth for HIV-1 DNA, indicating that he was
infected in utero (Table 1). The three remaining infants (0377, 0978
and 1021) were HIV-1 DNA negative at birth but were found positive
at 71, 55 and 67 days after birth, respectively. Because of these 3
infantswere not breastfed, HIV-1 transmission occurred duringdelivery
(intrapartum). Thirty-seven clones (9 from MIP 0377, 11 from MIP
0858, 12 from MIP 0978 and 5 from MIP 1021) were selected based
on the fact that they were representative of the diversity of the variantsTable 1
Characteristics of mother–infant pairs.
MIP Subject First positive Transmission Number clones
selected
Number clones
infectious
0377 Mother – 8 5
Infant 71 days ip 1 1
0978 Mother – 7 3
Infant 55 days ip 5 3
1021 Mother – 2 1
Infant 67 days ip 3 2
0858 Mother – 6 2
Infant at birth iu 5 0
ip: intrapartum.
iu: in utero.present in the mothers and their babies, and that they possessed or not
the PNGS at positions N301 and N384 (Fig. 1). Chimeric env genes were
constructed by insertion of the V1 to V5 env fragment in a NL4.3 env
backbone as previously described (Braibant et al., 2010), and the 37 cor-
responding Env-pseudotyped viruses were generated. Seventeen of
them were infectious in TZM-bl cells: 6 from MIP 0377, 2 from MIP
0858, 6 from MIP 0978 and 3 from MIP 1021 (Table 2, Fig. 1).
Sensitivity to neutralization by maternal plasma
We determined the sensitivity to neutralization of mother- and
infant-derived Env-pseudotyped viruses with the maternal plasma
collected during pregnancy just before the initiation of zidovudine
(ZDV) prophylaxis, 4 to 11 weeks before delivery. Maternal variants
issued from MIPs 0377, 0978 and 1021 were relatively resistant to
autologous neutralization. Indeed, 0377 maternal clones presented a
low sensitivity to neutralization (IC50 range: b20–103.1) and 0978
and 1021 maternal clones were particularly resistant to autologous
antibodies, failing to reach 50% neutralization even using a 1:20 dilu-
tion of plasma, the highest plasma concentration tested (Table 2).
Infant variants were also generally resistant to maternal plasma
(IC50 range: b20–28.7), except a single clone from pair 0978, clone
0978-I2, which on contrary, displayed a high sensitivity to maternal
plasma (IC50: 883; Table 2). In contrast, the two maternal clones
from MIP 0858, presented a high neutralization-sensitivity to mater-
nal autologous plasma with IC50 values of 1197 and 1642. However,
due to the lack of infectious infant clones for this pair, we were not
able to compare their susceptibility to the transmitted variant(s).
When the four pairs were considered together, we did not observe
any difference in sensitivity to autologous plasmas between mother
and infant variants (P=0.38, mixed model test; Fig. 2A).
Sensitivity to neutralization by heterologous sera
We investigated the sensitivity of maternal and infant variants to
neutralization by a pool of ten heterologous broadly neutralizing sera
selected from patients infected by CRF01_AE viruses in a previous
study (Samleerat et al., 2009). The seventeen clones presented a
broad and continuous range of sensitivity to heterologous antibodies
(IC50 range: 123–5543; Table 2). AmongMIP 0377, the infant clone pre-
sented a higher neutralization-sensitivity (IC50: 1056) compared to the
corresponding maternal clones (IC50 range: 123–339). On the contrary,
maternal clones from pairs 0978 and 1021 presented similar sensitivity
to heterologous neutralization (0978 IC50 range: 626–5543, 1021 IC50:
990) compared to infants clones (0978 IC50 range: 2277–4150; 1021
IC50: 585 and 746). When the four pairs were considered together, we
did not observe any difference in sensitivity to heterologous plasmas
between mother and infant variants (P=0.97, mixed model test;
Fig. 2B).
Sensitivity to neutralization by monoclonal antibodies
We tested the sensitivity of our pseudotyped viruses to neutraliza-
tion by the broadly neutralizing human monoclonal antibodies
(mAbs) b12, PG9 and PG16. b12 is directed against an epitope over-
lapping the CD4-binding site (CD4BS) (Burton et al., 1994; Saphire
et al., 2001), whereas PG9 and PG16 recognize a quaternary neutral-
izing epitope formed from conserved regions of V1/V2 and V3 vari-
able loops (Pancera et al., 2010; Walker et al., 2009). All maternal
and infant clones from MIPs 0377, 0978 and 1021, displayed a high
level of resistance to neutralization by mAb b12 (IC50>50 μg/mL),
whereas the two maternal clones from pair 0858 were highly sensi-
tive to b12 (IC50b0.1 μg/mL; Table 2). On the contrary, we observed
more heterogeneous results for PG9 and PG16 neutralization. Mater-
nal clones issued from MIPs 0377, 0978 and 1021 displayed a broad
and continuous range of sensitivity to both PG9 (IC50 range: 0.07 to
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Fig. 1. Phylogenetic analysis of env sequences derived frommother–infant pairs 0377, 0858, 0978 and 1021. A distance scale is given for each neighbor-joining tree. Bootstrap values
are expressed as percentages per 1000 replicates, and values above 50% are indicated on nodes. Each symbol denotes a single env sequence: ○, maternal sequence; ■, infant
sequence. The 37 clones selected for generating Env-pseudotyped viruses are encircled. Among these, the 17 infectious clones are hatched.
14 S. Thenin et al. / Virology 426 (2012) 12–21>10 μg/mL) and PG16 (IC50 range: 0.03 to >10 μg/mL) whereas all
infant clones were highly sensitive to both mAbs (PG9 IC50 range:
0.03–0.18 μg/mL; PG16 IC50 range: 0.01–0.36 μg/mL). When the four
MIPs were considered in aggregate, infant clones were signiﬁcantly
more sensitive to PG9 (P=0.04, mixed model test; Fig. 2C) and
PG16 (Pb0.01, mixed model test; Fig. 2D) compared to maternal
clones.
Viral infectivity in TZM-bl cells and PBMC
A selective advantage for the variants transmitted to the infants
could be the consequence of a higher viral infectivity. Therefore, weinvestigated the capacity of pseudotyped viruses to infect TZM-bl in-
dicator cells and primary stimulated-peripheral blood mononuclear
cells (PBMCs) in a single round of infection. Infectivity level of each
pseudotyped virus, whose quantity was normalized for p24 amount,
was compared with that of a pseudotyped virus expressing the enve-
lope of the NL4-3 reference strain (Table 2). Although infectivity
levels were globally higher in TZM-bl cells than in PBMCs, a high
correlation was observed between the two cell types (r=0.93;
Pb0.0001; Fig. 3C). A considerable variability in infectivity levels
was observed among maternal clones from MIP 0377 with two
clones, 0377-M2/M5, being poorly infectious and three clones,
0377-M1/M3/M4, being highly infectious (Table 2). Similarly, a high
Table 2
Summary of the biological properties of mother- and infant-derived Env-pseudotyped viruses.
Autologous Heterologous b12 PG9 PG16 Tropism sCD4 TAK-779 TZM-bl PBMC
MIP env clone (Genbank ID) N301 N384 plasma plasma (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) infectivity infectivity
0377-M1 (EU031223) − + 103.1 212 > 50 > 10 > 10 R5 1,74 0.039 16.8 0.67
0377-M2 (HQ875343) + − 31.9 339 > 50 0.31 1.98 R5 4,15 0.038 0.6 0.09
0377-M3 (EU031226) + − 20.4 123 > 50 1.46 3.31 R5 > 10 0.036 43.7 4.13
0377-M4 (EU0311227) + − 22.3 148 > 50 2.43 7.58 R5 > 10 0.056 31.3 3.27
0377-M5 (HQ875344) + − < 20 214 > 50 > 10 > 10 R5 3,19 0.038 0.3 0.05
0377-I1 (JQ003579) + + 28.7 1056 > 50 0.03 0.01 R5 2,97 0.019 4.5 0.25
0978-M1 (HQ875346) + + < 20 626 > 50 0.07 0.03 R5 5,71 0.086 3.1 0.22
0978-M2 (EU031126) + + < 20 5543 > 50 0.13 0.07 R5 >10 0.078 2.1 0.11
0978-M3 (HQ875347) + + < 20 3900 > 50 > 10 > 10 R5 0.15 0.021 0.4 0.10
0978-I1 (EU031128) + + < 20 2489 > 50 0.10 0.06 R5 > 10 0.062 5.7 0.43
0978-I2 (EU031141) + + 883 2277 > 50 0.18 0.16 R5 0.23 0.100 1.6 0.16
0978-I3 (EU031130) + + < 20 4150 > 50 0.11 0.04 R5 > 10 0.044 3.1 0.19
1021-M1 (JQ003580) + + < 20 990 > 50 0.86 0.48 R5 > 10 0.027 43.9 0.8
1021-I1 (EU031153) + + < 20 585 > 50 0.18 0.34 R5 3.59 0.039 45.1 0.64
1021-I2 (EU031150) + + < 20 746 > 50 0.14 0.36 R5 2.36 0.048 1.9 0.11
0858-M1(EU031374) − − 1197 2709 < 0.1 0.29 > 10 R5 > 10 0.008 4.6 0.19
0858-M2 (HQ875345) − − 1642 2112 < 0.1 > 10 > 10 R5 0.35 0.005 1.1 0.15
Sensitivity to neutralization by Functional properties
377
978
1021
858
The mAb neutralization and sCD4 inhibitory titers are color coded as follows: a red box indicates an IC50≤0.1 μg/mL, an orange box indicates 0.1 μg/mLb IC50≤10 μg/mL and a
yellow box indicates an IC50>10 μg/mL. For the plasma, the color codes are as follows: a red box indicates an IC50≥1:100 dilution, an orange box indicates 1:20≤ IC50b1:100
and a yellow box indicates an IC50b1:20. For the TZM-bl and PBMC infectivity, the color codes are as follows: a dark green box indicates an infectivity ratio (deﬁned as mean
RLU values obtained for the pseudotyped virus compared to mean RLU values obtained with the NL4-3 reference virus)≥10, a medium green box indicates 1.0≤ ratiob10 and a
light green box indicates a rationb1. Infant clones are highlighted in gray.
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1021-I1 being highly infectious when compared to clone 1021-I2,
much less infectious (Table 2). The infectivity levels of clones from
MIP 0978 were more homogeneous for both maternal and infantA B
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Fig. 3. Viral infectivity of mother- and infant-derived Env-pseudotyped viruses. The
capacity of maternal- (○) and infant- (■) derived Env-pseudotyped viruses to infect
(A) TZM-bl indicator cells and (B) primary stimulated-peripheral blood mononuclear
cells (PBMCs) was evaluated in a single round of infection. Results are expressed as
the ratio of mean RLU values obtained for each pseudotyped virus compared to mean
RLU values obtained with the NL4.3 reference virus. Comparisons between maternal
and infant-derived Env-pseudotyped viruses were done using a mixed model test.
(C) Correlation between TZM-bl and PBMC infectivity. The correlation coefﬁcient r
and P values were generated using Spearman's correlation test.
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To investigate whether the levels of Env processing and/or incor-
poration in virions contributed to differences in infectivity or had spe-
ciﬁc features in transmitted variants, we analyzed the expression of
Env glycoproteins on maternal and infant pseudotyped viruses by
western blot after electrophoresis under reducing and native condi-
tions (Figs. 4A–B). Before electrophoresis, viral proteins from pelleted
virions were solubilized and their quantity was normalized for p24
antigen (100 ng per well). Under reducing conditions and using poly-
clonal anti-gp120 antibody, we detected the expression of both
mature gp120 and uncleaved gp160 precursor in almost clones
(Fig. 4A). Despite some differences in the extent of processing between
clones,we could not detect obvious pattern in Env processing that could
distinguish infant from mother clones. Electrophoresis was performed
under native conditions to quantify the incorporation of Env under its
trimeric form in each variant. To avoid bias due to possible antigenic
differences between the various envelopes, we used the anti-gp412 F5 and 4E10 monoclonal antibodies to detect the envelope spikes in-
corporated since all envelope glycoproteins were chimeras containing
the same gp41 sequence derived from the NL4-3 virus. Using these
antibodies, we detected gp120-gp41 trimers but also various forms of
envelope glycoproteins, including gp120-gp41 monomers (~160 kDa)
and gp41 trimers (~140 kDa) (Fig. 4B). Analysis by densitometry of
the western blots showed that different levels of gp120-gp41 trimers
were incorporated into viruses (Fig. 4B). For most viruses, the level of
Env trimers incorporation correlated with the infectivity level, when
analyzing the ratio trimer/p24 (r=0.82, Pb0.0001; Fig. 4C). However,
despite variability in incorporation levels of Env trimers into virions,
these levels did not distinguish the maternal from the infant viruses
(P=0.23, mixed model test; Fig. 4D).
Sensitivity to entry inhibitors
The co-receptor usage of the infectious Env-pseudotyped viruses
was evaluated using U373-MAGI cell lines that stably express the
CD4 receptor and either the CCR5 or CXCR4 co-receptors. All viruses
exhibited a CCR5 tropism. We next investigated the sensitivity of
maternal and infant clones to soluble CD4 (sCD4) and TAK-779, a CCR5
antagonist. All maternal and infant exhibited a relatively homogeneous
sensitivity to TAK-779, with IC50 ranging from 0.019 to 0.100 μg/mL. No
statistically signiﬁcant difference was observed between maternal and
infant viruses (P=0.62, mixed model test; Fig. 5A). Sensitivity to sCD4
was considerably heterogeneous within the four mother–infant pairs
(IC50 range: 0.15 to >10 μg/mL) (Table 2). When clones from the four
MIPs were considered in aggregate, we did not observe any difference
in sensitivity to sCD4 between maternal and infant clones (P=0.60,
mixed model test; Fig. 5B). The sensitivity to sCD4 was associated with
infectivity: the most resistant variants were those that were most infec-
tious (r=0.54, P=0.02; Fig. 5C). In contrast, the sensitivity to sCD4 was
not associated with the level of Env trimers incorporation (r=0.25,
P=0.34; Fig. 5D).
Antigenic and functional properties according to PNGS at positions N301
and N384
The two PNGS at positions 301 and 384 were present in all infant
clones whereas they were not uniformly present in maternal clones.
Maternal clones from pair 0377 harbored either N301 or N384, with
one clone (0377-M1) N301− N384+ and four clones (0377-M2-M5)
N301+ N384−. The two maternal clones from pair 0858 were N301−
N384− whereas the three maternal clones from pair 0978 and the
unique maternal clone from pair 1021 were N301+ N384+. It should
be noted that given the small number of functional pseudotyped viruses
obtained, we could not test maternal clones from pairs 0978 and 1021
that were N301− and/or N384−, nor infant clones from pair 0858 that
were N301+ N384+. Nevertheless, our data suggested that the pres-
ence of N301 in presence or not of N384 conferred higher resistance
to autologous neutralization (P=0.01, Mann Whitney test). Indeed,
maternal clones 0377-M2 to M5 (N301+ N384−) and infant clone
0377-I1 (N301+ N384+) presented a higher resistance to autologous
neutralization (IC50 range: b20–31.9) compared to maternal clone
0377-M1 (N301− N384+; IC50: 103.1). All maternal and infant clones
from pairs 0978 and 1021 (N301+ N384+), except infant clone 0978-
I2, were highly resistant to autologous maternal plasma (IC50 b20)
whereas maternal clones from pair 0858 (N301− N384−) were highly
sensitive to autologous neutralization (IC50: 1197 and 1642). Moreover,
the absence of both PNGS at positions N301 and N384 compared to the
absence of N301 alone, could increase neutralization sensitivity. Indeed,
maternal clones frompair 0858 (N301−N384−)weremore sensitive to
autologous neutralization thanmaternal clones from pair 0377 (N301−
N384+ or N301+ N384−). All together, these results may suggest that
both N301 and N384 could be involved in sensitivity to autologous
neutralization.
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18 S. Thenin et al. / Virology 426 (2012) 12–21We next compared the functional properties according to the
presence or not of PNGS at positions N301 and/or N384. We observed
a wide range of sensitivity to sCD4 and infectivity levels whatever the
presence or not of N301 (sCD4 IC50 range: 0.15 to >10 μg/mL vs 0.35
to >10 μg/mL; TZM-bl cells range: 0.3 to 45.1 vs 1.1 to 16.8) or N384
(sCD4 IC50 range: 0.15 to >10 μg/mL vs 0.35 to >10 μg/mL; TZM-Bl
ratio range: 0.4 to 45.1 vs 0.4 to 43.7). These results suggested that
N301 and N384 PNGS did not seem to be involved in infectivity or
sensitivity to sCD4.
Discussion
During perinatal transmission of HIV-1, acquisition of a homoge-
neous genetic restricted viral population has been regularly observed,
suggesting the presence of selective pressures. The viral properties
of perinatally transmitted viruses remain incompletely understood.
In this study, we compared the biological properties of 17 Env-
pseudotyped viruses derived from variants of mother–infant pairs
infected by HIV-1 strains of the CRF01_AE clade. We determined
their sensitivity to neutralization by autologous and heterologous
sera as well as by broadly neutralizing mAbs. We did not ﬁnd any
signiﬁcant difference in neutralization sensitivity between maternal
and infant clones by either autologous or heterologous sera. However,
it should be noted that in most cases maternal variants displayed a
low or undetectable neutralizing sensitivity to autologous maternal
plasma. As maternal plasma samples were collected before the timing
at which env sequences were obtained, it may be possible that mater-
nal clones had started to evolve to escape earlier antibodies. Never-
theless, one variant in an infant (clone 0978-I2 from pair 0978) was
more sensitive to autologous maternal plasma than all tested mater-
nal variants. Its presence in the infant suggested a low impact of
maternal antibodies on the selection of transmitted variants. This
observation conﬁrmed recent studies suggesting that the genetic
bottleneck in vertical transmission is not driven by selection of
neutralization-resistant variants from the maternal viral population(Kishko et al., 2011; Russell et al., 2011). The data obtained with
b12 could not be compared between maternal and infant clones
since most of them (15/17) were found resistant to this antibody.
This low susceptibility to b12 is consistent with a recent phenotypic
study that showed that only one out of 35 CRF01_AE Env-recombinant
viruses was susceptible to b12 (Utachee et al., 2009). In contrast, all
the transmitted viruses in the infants were highly sensitive to PG9
and PG16 (IC50b0.2 μg/mL andb0.4 μg/mL, respectively), signiﬁcantly
more sensitive than the maternal variants. This observation might indi-
cate that PG9/PG16-sensitive variants would exhibit functional proper-
ties conferring a selective advantage for the mother-to-infant
transmission. If conﬁrmed in a larger population, it would suggest that
PG9 and/or PG16might be interesting for immunoprophylaxis of MTCT.
All maternal and infant clones were R5-tropic and similarly sensi-
tive to TAK-779, a CCR5 antagonist. In contrast, both maternal and
infant clones displayed a heterogeneous sensitivity to sCD4, but no
statistically signiﬁcant difference was observed between maternal
and infant clones. This is consistent with a recent study performed
on 5 clade B MIPs, in which all infant clones exhibited a wide range
of sCD4 sensitivity, similar to that of maternal clones (Kishko et al.,
2011). Our study also indicated that the viral infectivity levels in a
single round of infection of both TZM-bl cells and PBMCs did not
differ between maternal and infant variants despite a considerable
variability in both variants. Working with pseudotyped viruses, we
could not compare their replicative ﬁtness in multiple rounds of in-
fection and we cannot exclude a better replicative ﬁtness of transmit-
ted viruses. Previous studies performed on clade C MIPs have shown
higher rates of replicative ﬁtness of transmitted viruses than non-
transmitted viruses despite, asweobserved, a lack of difference between
their infectivity levels (Kong et al., 2008; Zhang et al., 2010a). Similarly
to susceptibility to sCD4 and infectivity levels, our data of Env processing
efﬁciency and Env trimers incorporation levels did not seem to differ
between maternal and infant clones. However, we observed that higher
levels of Env trimers incorporation in virus particles correlated with
increased infectivity levels. The most infectious virions were also those
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sCD4was not linked to a higher trimers density. Although several modes
of sCD4-mediated inhibition were described, i.e. competitive inhibition,
gp120 shedding (Moore et al., 1991; Orloff et al., 1993) or short-lived
activated state of gp120 (Haim et al., 2009), these results suggested a
decreased afﬁnity of the envelope glycoprotein trimer of themost infec-
tious virions for sCD4 and a possible biological advantage of virions
expressing trimers adopting a conformation that better occludes the
CD4 binding site. Together, these results suggested that the quantity
of Env trimers rather than their afﬁnity for the CD4 receptor, by facilitat-
ing the interaction with the CD4 receptor at the cell surface, modulates
the infectivity of virions. Because all our pseudotyped viruses harbor the
same transmembrane glycoprotein derived from NL4.3 prototype
strain, the differences in Env incorporation must be attributed to the
gp120 region only.
We previously observed a high degree of conservation of two
PNGS in infant viruses, at positions N301 in V3 and N384 in C3, and
hypothesized that they may confer a selective advantage for trans-
mission of the virus to infants (Samleerat et al., 2008). We therefore
compared the antigenic and functional properties of pseudotyped
viruses according to the presence or not of N301 and/or N384. Despite
the low number of functional viruses obtained, we could make some
observations conﬁrming that these two PNGS may play a role in resis-
tance to autologous sera. This is consistent with previous studies that
showed by in vitro studies that N301 was associated with a decrease
in sensitivity of HIV-1 to neutralization by CD4BS antibodies
(Koch et al., 2003; Malenbaum et al., 2000). However, PNGS at
these two positions were not associated with infectivity or sensitivity
to sCD4.
In conclusion, although limited in samples size, our study suggests
that both the founder/transmitted viruses of the CRF01_AE clade pre-
sent in infants and the variants present in their chronically infected
mothers display a wide spectrum of biological properties, albeit the
genetic bottleneck that occurred during transmission. Neither Env
processing, Env incorporation efﬁciency, infectivity level, nor sensi-
tivity to sCD4 or TAK-779 was associated with transmission. In
other words, we did not ﬁnd any speciﬁc property that would explain
the selection of the founder/transmitted viruses, except sensitivity to
PG9 and PG16. Maternal variants were less sensitive to neutralization
by PG9 and PG16 than the founder/transmitted variants present in
the infants. These data may suggest that the development of resis-
tance to these antibody speciﬁcities could have some detrimental
effect for the mother-to-child transmission of HIV-1. This observation
may have implications for the development of prophylactic strategies
to prevent MTCT.
Materials and methods
Study population
We selected samples from four mother–infant pairs (# 0377, 0858,
0978 and 1021) enrolled in the “Perinatal HIV Prevention Trial” cohort
(Lallemant et al., 2000), that were described in a previous study
(Samleerat et al., 2008). Env clones from these four pairs corresponded
to a 1.2 kb fragment of the VI–V5 region covering almost the entire
HIV-1 env gp120 gene (fromupstreamV1 to downstreamV5) previously
cloned in pCR2.1 vector (Invitrogen). Accession numbers are indicated
in Table 2.
Construction of chimeric env genes
In order to obtain complete gp160 env, we constructed chimeric
env genes in a NL4.3 backbone as described previously (Braibant et
al., 2010). Brieﬂy, the complete gp160 NL4.3 env gene was inserted
into the EcoRI site of the pCR2.1 vector. Part of the env gene coding
for V1 to V5 regions was extracted from this construct using NdeIand MfeI restriction (New England BioLabs) and replaced by the cor-
responding gp120 sequence of interest excised from the pCR2.1 vector
by digestion with the same enzymes. Chimeric env genes containing
each gp120 sequence inserted in the NL4.3 backbone were then sub-
cloned into the EcoRI site of the pCI expression vector (Promega).
Generation of env-pseudotyped viruses
Env-pseudotyped viruses were generated as described previously
(Samleerat et al., 2009). 3.5×106 293T cells were cotransfected with
12 μg of each pCI-env plasmid and 8 μg of pNL4.3.LUC.R-E- (Connor et
al., 1995), using phosphate calcium (Invitrogen). Viral supernatants
were collected 72 h later, puriﬁed by ﬁltration (0.45 μm ﬁlter) and
stored as aliquots at−80 °C. Viral infectivity was monitored by infec-
tion of 1×104 TZM-bl cells with 100 μL of serial 5-fold dilutions of the
viral supernatants in quadruplicate in the presence of 30 μg/mL of
DEAE-dextran. Infection levels were determined after 48 h, using
the Bright Glo luciferase assay (Promega) and a Centro LB 960 lumin-
ometer (Berthold Technologies) to measure luciferase activity in cell
lysates. Results with Relative Light Unit (RLU) values >2.5 times the
negative control (cells alone) were considered positive.
Cell culture
293T and U373-MAGI cell lines were grown at 37 °C and 5% CO2 in
Dulbecco's modiﬁed Eagle's medium (DMEM) containing 10% heat-
inactivated fetal calf serum (FCS) and antibiotics (100 IU of penicillin
and 100 μg/mL of streptomycin). U373-MAGI-CXCR4 and U373-
MAGI-CCR5 cells were cultured in medium supplemented with 1 μg/
mL of puromycin and 100 μg/mL of hygromycin B. TZM-bl cells were
maintained in DMEM+pyruvate supplemented with 10% FCS,
50 μg/mL of gentamicin and 25 mM of HEPES (Platt et al., 1998; Wei
et al., 2002). Frozen peripheral blood mononuclear cells (PBMC)
from HIV-1 negative blood donors were treated with 5 μg/mL of phy-
tohemagglutinin in RPMI 1640medium supplemented with 10 ng/mL
of interleukin-2 (Roche), 20% FCS and antibiotics for 3 days. They
were then washed and maintained in RPMI 1640 medium supple-
mented with interleukin-2, 20% FCS and antibiotics.
Determination of co-receptor usage
Co-receptor usage was determined using the U373-MAGI cell
lines. U373-MAGI cells expressed the CD4 receptor with either the
CXCR4 co-receptor (U373-MAGI-CXCR4) or the CCR5 co-receptor
(U373-MAGI-CCR5). 1.5×104 cells were plated the day prior infec-
tion. Cells were infected with 25 μL of a normalized p24 amount
(10 ng) of pseudotyped viruses for 2 h at 37 °C. Then, 175 μL of
DMEM supplemented with 20 μg/mL of DEAE-dextran and 5% FCS
were added. 48 h after infection, the luciferase activity was measured
and the viral tropism was determined.
Neutralization and inhibition assay
Sensitivity to autologous and heterologous plasmas, mAbs b12,
PG9 and PG16, and to sCD4 and TAK-779 entry inhibitors, were
assessed in duplicate in TZM-bl cells. After titration, pseudotyped
virus stocks were diluted to obtain 1000 TCID50/mL in growthmedium.
Aliquots of 25 μL were then incubated for 1 h at 37 °C with 75 μL of
either two-fold serial dilutions of heat-inactivated serum (1:20 to
1:10240), or b12 (50 μg/mL to 0.1 μg/mL; Polymun Scientiﬁc), or sCD4
(10 μg/mL to 0.02 μg/mL; NIBSC), or three-fold serial dilutions of PG9
and PG16 (10 μg/mL to 0.005 μg/mL; IAVI). Then 1×104 TZM-bl cells
were added to the virus/serum mixture in the presence of 30 μg/mL
of DEAE-dextran. Luciferase activity was measured 48 h after infection
as described above. Results were expressed as mean values. IC50 values
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centration required to reduce RLUs by 50%.
For TAK-779 inhibition, 8×103 TZM-bl cells per wells were pre-
pared the day prior infection. Cells were ﬁrst treated for 1 h with 75 μL
of two-fold serial dilutions of TAK-779 (0.2 μg/mL to 0.0004 μg/mL;
NIH AIDS Research and Reference Reagent Program) before adding
25 μL of pseudotyped viruses normalized to 1000 TCID50/mL. 100 μL of
DMEM medium supplemented with 30 μg/mL DEAE-dextran were
then added to cells. Luciferase activity wasmeasured 48 h after infection
as described above.
Viral infectivity in TZM-bl cells and peripheral blood mononuclear cells
Viral infectivity was determined in quadruplicate in TZM-bl and
PBMC cells. 25 μL of virus stock normalized at 10 ng p24 were
added to 75 μL of culture medium. 1×104 TZM-bl cells or 1×105
PBMC cells were added to viruses in the presence of 30 μg/mL
DEAE-dextran. Luciferase activity was measured in the cells lysates
48 h after infection. Results were expressed as a ratio of mean RLU
values obtained for each virus compared to mean RLU values obtained
with the NL4.3 virus.
Processing and incorporation of envelope glycoproteins
Viral supernatants were overlaid on a 20% sucrose cushion, and
viral particles were pelleted at 87,000 g for 1.5 h at 4 °C. Viral pellets
were solubilized for 5 min in 100 μL of phosphate buffered saline
(PBS) supplemented with 1% Triton X-100 and an antiprotease cock-
tail (aprotinine 2 μg/mL, leupeptine 2 μg/mL, phenylmethanesulfo-
nylﬂuoride 1 mM). P24 antigen content was determined by ELISA
(INNOTEST® HIV Antigen mAb; Innogenetics) and aliquots of the
resuspended pellets were stored as at −80 °C until used. Glycopro-
teins analyses were performed by western blotting after SDS-PAGE
and Blue-Native-PAGE (BN-PAGE).
SDS-PAGE
Samples containing 100 ng p24 were boiled for 5 min in Laemmli
sample buffer in the presence of dithiothreitol, and were separated by
electrophoresis in a SDS-10% polyacrylamide gel. The proteins were
then transferred onto a nitrocellulose membrane for 1.5 h at 100 V.
Blots were probed for gp120 and p24 with speciﬁc goat polyclonal
antibodies (1/1000; AbD Serotec) in Tris buffer saline (TBS) containing
2% nonfat milk by incubation overnight at 4 °C, followed after washings
by incubation with a horseradish peroxidase (HRP) conjugated anti-
goat-IgG from rabbit (1/5000; Jackson ImmunoResearch) for 1 h at
room temperature. Immunoblots were developed using a luminol-
based enhanced chemiluminescence substrate (ECL Plus Western Blot-
ting Detection System; Amersham). Env gp120 and gp160, as well as
p24 proteins were quantiﬁed using the Bio-1D++ analysis software
(Vilber Lourmat; Deutschland GmbH).
BN-PAGE
To analyze Env gp under native conditions, we used a modiﬁed
BN-PAGE protocol (Binley et al., 2010; Crooks et al., 2007; Moore et
al., 2006). Solubilized virions were normalized for p24 amount
(100 ng). 2× native sample buffer (125 mM Tris–HCl pH 6.8, 40%
glycerol, 0.1% Coomassie blue G250) was added to samples prior to
loading onto a 4 to 15% Mini-PROTEAN® TGX™ gel (BioRad). High
molecularweight calibration Kit for native electrophoresis (Amersham)
was used for size determination. Samples were separated at 4 °C for
2.5 h at 100 V with TG 1X (25 mM Tris–192 mM Glycine) containing
0.002% Coomassie blue as cathode buffer and TG 1× as anode buffer.
The gel was then transferred onto a polyvinylidene diﬂuoride (PVDF)
membrane for 1.5 h at 100 V. PVDF membranes were destained with
a 30% methanol/10% acetic acid solution, then with 100% methanol.
Blots were probed with mAbs 2 F5 and 4E10 (1 μg/mL; Polymun)in TBS containing 2% nonfat milk by incubation overnight at 4 °C, fol-
lowed after washings by incubation with a horseradish peroxidase
(HRP) conjugated anti-human-IgG from goat (1/5000; Jackson Immu-
noResearch) for 1 h at room temperature. Immunoblots were developed
with a luminol-based enhanced chemiluminescence substrate (ECL Plus
Western Blotting Detection System; Amersham). Env trimers were
quantiﬁed using the Bio-1D++ analysis software (Vilber Lourmat;
Deutschland GmbH).
Statistical analyses
A mixed-model approach was used to compare each biological
property between maternal and infant clones. This is the most suit-
able technique for estimating differences according to the origin
(maternal or infant) of the clone, with allowance for the correlation
structure of properties within each MIP and for differences in the
number of observations within each MIP. For each property, the ori-
gin of the clone was considered as the ﬁxed effect and MIP's effect
was assumed to be random. In cases in which the IC50 values were
b20, the midpoint value between 0 and 20, 10, was assigned. When
the IC50 values were >10, a value of 10 was assigned. Signiﬁcance
was reported when P≤0.05. Correlations between two biological
properties were examined with the Spearman's correlation test. Bio-
logical properties according to PNGS at positions N301 or N384
were compared with the Mann–Whitney test.
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